Physician profile
Bryan C Doonan
NPI 1427167121
$5,483.65
in general payments reported to CMS, 2019-2025
45 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $571 · 2021: $754 · 2022: $470 · 2023: $437 · 2024: $1,005 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.33 | 2021-2025 | Botox, Dalvance |
| Astrazeneca Pharmaceuticals Lp | $635.65 | 2021-2025 | Airsupra, Breztri |
| Allergan, INC. | $443.39 | 2019-2022 | |
| Exact Sciences Corporation | $414.75 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merz North America, INC. | $329.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $194.79 | 2019-2024 | Arexvy, Shingrix |
| Pfizer INC. | $178.00 | 2019-2025 | |
| Lilly USA, LLC | $169.19 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Lumenis Be INC | $145.69 | 2025 | M22 |
| Genentech USA, INC. | $143.43 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $135.42 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $131.46 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Medtronic Vascular, INC. | $115.46 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Doonan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.